https://www.ucb.com/ 2026-02-27T14:48:59+01:00 daily 1.0 https://www.ucb.com/home 2026-02-27T14:48:59+01:00 0.5 https://www.ucb.com/sitemap 2024-11-07T11:39:15+01:00 0.5 https://www.ucb.com/node/41 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/search 2024-11-12T05:57:22+01:00 0.5 https://www.ucb.com/legal 2024-11-25T10:18:01+01:00 0.5 https://www.ucb.com/about-ucb 2026-02-18T10:17:04+01:00 0.5 https://www.ucb.com/about-ucb/management 2026-01-14T10:48:33+01:00 0.5 https://www.ucb.com/our-company/green-strategy 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/about-ucb/collaborate-with-us/partnering 2025-08-11T16:16:17+02:00 0.5 https://www.ucb.com/about-ucb/collaborate-with-us/suppliers 2025-08-12T12:02:38+02:00 0.5 https://www.ucb.com/disclosure-of-payments 2024-11-06T17:10:35+01:00 0.5 https://www.ucb.com/Cookie-policy 2024-11-25T10:24:12+01:00 0.5 https://www.ucb.com/Support-of-patient-organisations-in-Europe 2026-01-29T08:57:50+01:00 0.5 https://www.ucb.com/investors/IR-team 2024-04-08T11:20:14+02:00 0.5 https://www.ucb.com/investors/shareholders/Transparency-notifications 2025-10-10T08:49:46+02:00 0.5 https://www.ucb.com/investors/shareholders/Share-repurchase-program 2024-11-22T06:13:13+01:00 0.5 https://www.ucb.com/investors/shareholders/Notification-Art-74 2025-10-27T11:47:21+01:00 0.5 https://www.ucb.com/investors/shareholders/Shareholders-meeting-2021 2024-11-22T06:09:34+01:00 0.5 https://www.ucb.com/investors/shareholders/Shareholders-meeting-2019 2024-11-22T06:11:34+01:00 0.5 https://www.ucb.com/investors/shareholders/Shareholders-meeting-2017 2024-11-22T06:12:11+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2013-Disclaimer 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2015-Disclaimer 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2021-Disclaimer 2024-11-21T17:21:53+01:00 0.5 https://www.ucb.com/investors/Download-center/Exchange-offer-Disclaimer 2024-11-21T17:23:00+01:00 0.5 https://www.ucb.com/investors/Download-center/EMTN-2022-program-disclaimer 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/shareholders/Shareholders-meeting-2020 2024-11-22T06:11:03+01:00 0.5 https://www.ucb.com/investors/Download-center/EMTN-Note-Disclaimer 2024-11-21T17:21:01+01:00 0.5 https://www.ucb.com/investors/shareholders/Shareholders-meeting-2018 2024-11-22T06:11:55+01:00 0.5 https://www.ucb.com/investors/UCB-shareholders/Shareholders-meeting-2016 2024-11-21T20:30:13+01:00 0.5 https://www.ucb.com/solutions/products/cimzia-axial-spondyloarthritis-axspa 2025-09-25T09:49:08+02:00 0.5 https://www.ucb.com/solutions/products/cimzia-crohn-s-disease 2025-09-25T09:49:43+02:00 0.5 https://www.ucb.com/solutions/products/cimzia-plaque-psoriasis 2025-09-25T09:50:29+02:00 0.5 https://www.ucb.com/solutions/products/cimzia-psoriatic-arthritis 2025-09-25T09:51:01+02:00 0.5 https://www.ucb.com/solutions/products/cimzia-rheumatoid-arthritis 2025-09-25T09:51:34+02:00 0.5 https://www.ucb.com/solutions/products/vimpat 2024-11-26T10:14:09+01:00 0.5 https://www.ucb.com/solutions/products/briviact-epilepsy 2025-09-01T10:50:26+02:00 0.5 https://www.ucb.com/solutions/products/keppra 2024-11-26T10:11:35+01:00 0.5 https://www.ucb.com/solutions/products/neupro-parkinson-s-disease 2024-11-26T10:12:48+01:00 0.5 https://www.ucb.com/solutions/products/neupro-restless-legs-syndrome 2024-11-26T10:13:30+01:00 0.5 https://www.ucb.com/innovation/clinical-studies 2026-02-25T15:08:30+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index 2025-11-07T11:57:17+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/plain-language-summaries 2026-01-27T15:31:42+01:00 0.5 https://www.ucb.com/innovation/pipeline 2026-02-26T11:54:52+01:00 0.5 https://www.ucb.com/about-ucb/collaborate-with-us/suppliers/requisition-to-pay-process 2026-02-09T13:44:57+01:00 0.5 https://www.ucb.com/solutions/diseases/rheumatoid-arthritis 2024-11-06T11:29:39+01:00 0.5 https://www.ucb.com/solutions/diseases/axial-spondyloarthritis 2025-01-07T14:13:41+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/data-transparency-policy 2024-11-05T18:02:08+01:00 0.5 https://www.ucb.com/solutions/diseases/psoriatic-arthritis 2024-11-19T15:16:33+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/faq 2024-11-05T17:56:52+01:00 0.5 https://www.ucb.com/solutions/diseases/parkinson-s-disease 2025-01-07T14:14:24+01:00 0.5 https://www.ucb.com/newsroom/contact 2025-08-11T16:41:36+02:00 0.5 https://www.ucb.com/newsroom 2026-02-10T17:15:11+01:00 0.5 https://www.ucb.com/solutions/diseases/psoriasis 2024-11-26T11:26:18+01:00 0.5 https://www.ucb.com/solutions/diseases/osteoporosis 2025-10-20T08:36:03+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/data-transparency-policy/results-on-public-registries 2025-08-11T11:48:46+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/data-transparency-policy/peer-reviewed-publications 2024-11-08T11:02:18+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/data-transparency-policy/study-reports-and-synopses 2024-11-25T11:46:56+01:00 0.5 https://www.ucb.com/clinical-studies/Clinical-studies-index/Glossary 2024-01-22T16:22:45+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/data-transparency-policy/plain-language-summaries-of-research-results 2024-11-05T17:54:43+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/data-transparency-policy/access-to-patient-level-clinical-study-data 2026-01-05T14:02:37+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-at-ucb-how-are-medicines-made-and-tested 2025-01-07T11:03:29+01:00 0.5 https://www.ucb.com/solutions/diseases 2026-02-26T13:28:51+01:00 0.5 https://www.ucb.com/stories-media/Press-Releases/Form 2024-11-21T16:38:10+01:00 0.5 https://www.ucb.com/solutions/healthcare-professionals/overview 2025-06-16T11:06:22+02:00 0.5 https://www.ucb.com/ucb-worldwide 2025-02-24T11:37:11+01:00 0.5 https://www.ucb.com/contact/contact 2024-11-18T09:36:26+01:00 0.5 https://www.ucb.com/contact-us 2025-06-16T10:57:57+02:00 0.5 https://www.ucb.com/solutions/products 2025-09-25T11:21:24+02:00 0.5 https://www.ucb.com/solutions/products/nayzilam 2024-11-26T10:12:09+01:00 0.5 https://www.ucb.com/solutions/products/evenity 2024-11-26T10:10:45+01:00 0.5 https://www.ucb.com/solutions/products/cimzia-ankylosing-spondylitis 2025-09-25T09:48:29+02:00 0.5 https://www.ucb.com/innovation/drug-discovery 2025-08-12T14:39:52+02:00 0.5 https://www.ucb.com/contact-us/integrity-line 2024-11-08T13:55:47+01:00 0.5 https://www.ucb.com/about-ucb/sustainability/environmental-sustainability/co2e/sustainable-packaging 2025-01-27T11:28:46+01:00 0.5 https://www.ucb.com/innovation/funding 2025-04-16T15:48:07+02:00 0.5 https://www.ucb.com/innovation/funding/grants 2025-11-17T17:28:24+01:00 0.5 https://www.ucb.com/newsroom/downloads 2024-11-06T17:19:42+01:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals 2025-02-19T15:04:06+01:00 0.5 https://www.ucb.com/newsroom/ucb-stories 2024-11-06T14:56:00+01:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/other-countries 2026-02-13T09:31:25+01:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/belgium 2024-11-06T16:50:44+01:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/denmark 2025-01-27T15:24:56+01:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/finland 2025-06-03T10:52:11+02:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/hungary 2025-07-01T09:40:06+02:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/ireland 2026-02-25T15:24:46+01:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/italy 2025-06-27T16:23:47+02:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/netherlands 2025-06-04T11:37:17+02:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/norway 2025-06-11T10:59:12+02:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/romania 2025-06-20T16:21:41+02:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/sweden 2025-02-07T11:34:01+01:00 0.5 https://www.ucb.com/disclosure-of-payments/disclosure-of-payments-to-healthcare-professionals/ukraine 2024-11-06T17:06:17+01:00 0.5 https://www.ucb.com/about-ucb/collaborate-with-us/suppliers/become-our-supplier 2024-11-06T14:17:58+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies 2024-11-05T17:49:43+01:00 0.5 https://www.ucb.com/newsroom/press-releases 2024-11-14T09:20:05+01:00 0.5 https://www.ucb.com/press-office/Overview 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/UCB-financials/Full-year-financial-results 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/UCB-financials/Half-year-financial-results 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/node/12071 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/UCB-guest-wireless-network-policies 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/solutions/products/bimzelx 2024-12-10T10:33:19+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2021-documents 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/Download-center/EMTN-notes-documents 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2013-documents 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/Download-center/Exchange-offer-documents 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2015-Documents 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/HCP-policies 2025-01-09T14:38:49+01:00 0.5 https://www.ucb.com/about-ucb/animal-welfare 2025-05-28T09:14:59+02:00 0.5 https://www.ucb.com/solutions/healthcare-professionals/women-of-childbearing-age 2025-02-07T13:48:43+01:00 0.5 https://www.ucb.com/solutions/healthcare-professionals/pregnancy-and-lactation-studies 2024-12-20T15:12:57+01:00 0.5 https://www.ucb.com/solutions/healthcare-professionals/women-of-childbearing-age/clinical-guidelines 2025-01-10T12:02:06+01:00 0.5 https://www.ucb.com/investors 2026-03-13T18:41:05+01:00 0.5 https://www.ucb.com/investors/equity-story 2026-03-13T18:41:45+01:00 0.5 https://www.ucb.com/investors/shareholders 2026-03-27T07:17:00+01:00 0.5 https://www.ucb.com/investors/corporate-governance 2026-03-13T18:43:09+01:00 0.5 https://www.ucb.com/investors/performance 2026-03-13T18:42:24+01:00 0.5 https://www.ucb.com/investors/download-center 2026-03-24T14:44:52+01:00 0.5 https://www.ucb.com/investors/shareholders/Shareholders-meeting-2022 2024-11-22T06:09:11+01:00 0.5 https://www.ucb.com/about-ucb/ethics-and-business-integrity 2025-11-24T10:40:54+01:00 0.5 https://www.ucb.com/investors/download-center/rozanolixizumab 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/solutions/diseases/hidradenitis-suppurativa 2025-12-18T14:59:44+01:00 0.5 https://www.ucb.com/about-ucb/sustainability/environmentals-sustainability/co2e 2026-03-23T16:14:03+01:00 0.5 https://www.ucb.com/about-ucb/sustainability/environmentals-sustainability/conserving-water 2026-02-27T14:52:48+01:00 0.5 https://www.ucb.com/about-ucb/sustainability/environmentals-sustainability/reducing-waste 2026-02-27T14:30:23+01:00 0.5 https://www.ucb.com/investors/download-center/rozanolixizumab-pop-up 2024-11-26T09:27:46+01:00 0.5 https://www.ucb.com/about-ucb/sustainability 2026-02-26T11:49:32+01:00 0.5 https://www.ucb.com/our-company/Sustainability/UCB-Materiality-Update-Results 2025-09-29T09:50:38+02:00 0.5 https://www.ucb.com/about-ucb/sustainability/environmental-sustainability 2025-06-19T16:26:44+02:00 0.5 https://www.ucb.com/solutions/products/fintepla 2025-10-16T11:11:40+02:00 0.5 https://www.ucb.com/investors/download-center/zilucoplan 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/download-center/zilucoplan-pop-up 2024-11-26T09:28:39+01:00 0.5 https://www.ucb.com/investors/download-center/bimekizumab 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/download-center/bimekizumab-pop-up 2024-11-25T17:56:36+01:00 0.5 https://www.ucb.com/innovation/capabilities 2024-11-07T14:26:01+01:00 0.5 https://www.ucb.com/node/14681 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/innovation/innovation-is 2025-08-12T14:36:35+02:00 0.5 https://www.ucb.com/ucbcares 2025-03-25T10:29:59+01:00 0.5 https://www.ucb.com/innovation 2025-11-05T15:39:02+01:00 0.5 https://www.ucb.com/solutions/diseases/dravet-syndrome 2025-08-12T17:25:09+02:00 0.5 https://www.ucb.com/solutions/diseases/epilepsy-and-rare-syndromes 2026-02-06T08:30:53+01:00 0.5 https://www.ucb.com/node/14750 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/shareholders/UCB-analyst-contacts 2026-03-10T09:56:33+01:00 0.5 https://www.ucb.com/node/14771 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/shareholders/Shareholders-meeting-2023 2024-11-22T06:08:47+01:00 0.5 https://www.ucb.com/solutions/diseases/neurology 2025-03-19T15:39:10+01:00 0.5 https://www.ucb.com/solutions/diseases/myasthenia-gravis 2025-10-22T14:14:15+02:00 0.5 https://www.ucb.com/node/14827 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/solutions/Women-of-Childbearing-Age 2025-04-16T15:41:03+02:00 0.5 https://www.ucb.com/solutions/healthcare-professionals/immune-to-the-impossible 2025-01-07T14:12:56+01:00 0.5 https://www.ucb.com/investors/download-center/2023-HY-Replay 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/solutions/products/rystiggo 2026-01-14T11:00:36+01:00 0.5 https://www.ucb.com/about-ucb/our-positions 2026-01-14T12:09:25+01:00 0.5 https://www.ucb.com/about-ucb/collaborate-with-us/responsible-procurement 2025-11-24T08:20:41+01:00 0.5 https://www.ucb.com/403 2025-01-13T11:17:03+01:00 0.5 https://www.ucb.com/investors/Download-center/2023-Retail-Bond-Disclaimer 2024-11-21T17:19:36+01:00 0.5 https://www.ucb.com/investors/Download-center/2023-Retail-Bond-Documents 2024-03-05T14:09:38+01:00 0.5 https://www.ucb.com/solutions/products/zilbrysq 2026-01-26T17:09:38+01:00 0.5 https://www.ucb.com/solutions/diseases/parkinson-s-disease/pecpr 2024-12-02T16:23:29+01:00 0.5 https://www.ucb.com/solutions/diseases/parkinson-s-disease/pecpr/vikas-story 2024-11-04T11:21:50+01:00 0.5 https://www.ucb.com/solutions/diseases/parkinson-s-disease/pecpr/carol-s-story 2024-11-04T11:24:08+01:00 0.5 https://www.ucb.com/solutions/diseases/parkinson-s-disease/pecpr/harold-s-story 2024-11-04T11:22:50+01:00 0.5 https://www.ucb.com/solutions/diseases/parkinson-s-disease/pecpr/shah-s-story 2024-11-04T11:25:52+01:00 0.5 https://www.ucb.com/innovation/funding/investigator-initiated-studies 2026-03-27T10:51:06+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2015-Documents-Archive 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/Download-center/EMTN-notes-documents-Archive 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2021-documents-Archive 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/investors/Download-center/2023-EMTN-program 2024-03-05T13:41:13+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2015-Disclaimer-Archive 2024-11-21T17:24:39+01:00 0.5 https://www.ucb.com/investors/Download-center/EMTN-notes-Disclaimer-Archive 2024-11-21T17:25:01+01:00 0.5 https://www.ucb.com/investors/Download-center/Eurobond-2021-Disclaimer-Archive 2024-11-21T17:25:28+01:00 0.5 https://www.ucb.com/investors/Download-center/2023-EMTN-program-Disclaimer 2024-11-21T17:25:59+01:00 0.5 https://www.ucb.com/investors/IR-team/Feedback 2024-11-25T15:44:53+01:00 0.5 https://www.ucb.com/General-Patient-Privacy-Notice-local_versions 2025-01-09T14:40:33+01:00 0.5 https://www.ucb.com/solutions/healthcare-professionals/podcasts 2024-11-25T17:28:39+01:00 0.5 https://www.ucb.com/solutions/diseases/parkinson-s-disease/pecpr/marc-van-grieken 2024-11-04T11:27:10+01:00 0.5 https://www.ucb.com/investors/shareholders/Shareholders-meeting-2024 2026-01-26T16:55:54+01:00 0.5 https://www.ucb.com/investors/Download-center/2024-Eurobond-Disclaimer 2024-11-21T17:22:28+01:00 0.5 https://www.ucb.com/investors/Download-center/2024-Eurobond-Documents 2024-03-20T08:30:24+01:00 0.5 https://www.ucb.com/solutions/diseases/tk2d 2025-08-21T16:25:20+02:00 0.5 https://www.ucb.com/about-ucb/sustainability/inclusion 2026-02-27T14:34:21+01:00 0.5 https://www.ucb.com/about-ucb/sustainability/patient-engagement 2026-02-27T14:27:30+01:00 0.5 https://www.ucb.com/about-ucb/sustainability/health-safety-and-well-being 2026-02-27T14:31:44+01:00 0.5 https://www.ucb.com/solutions/healthcare-professionals/rheumacensus 2024-11-22T05:53:23+01:00 0.5 https://www.ucb.com/solutions 2026-02-17T17:13:40+01:00 0.5 https://www.ucb.com/solutions/diseases/lupus 2025-01-07T14:40:29+01:00 0.5 https://www.ucb.com/solutions/diseases/LGS 2025-02-24T11:31:18+01:00 0.5 https://www.ucb.com/our-company/collaborate-with-us 2025-03-20T15:34:55+01:00 0.5 https://www.ucb.com/innovation/publications 2024-11-19T11:27:53+01:00 0.5 https://www.ucb.com/solutions/diseases/immunology 2025-03-19T15:30:45+01:00 0.5 https://www.ucb.com/about-ucb/sustainability/equitable-access-to-medicines 2026-02-27T14:25:42+01:00 0.5 https://www.ucb.com/solutions/healthcare-professionals/podcasts/fragility-fractures-in-focus 2024-11-20T10:37:16+01:00 0.5 https://www.ucb.com/solutions/healthcare-professionals/podcasts/under-the-skin 2024-11-20T19:18:33+01:00 0.5 https://www.ucb.com/solutions/diseases/CDKL5-deficiency-disorder 2024-12-11T12:33:27+01:00 0.5 https://www.ucb.com/solutions/Women-of-Childbearing-Age/Creating-value-through-action 2024-12-20T14:11:10+01:00 0.5 https://www.ucb.com/investors/UCB-shareholders/Shareholders-meeting-2025 2026-03-25T11:22:01+01:00 0.5 https://www.ucb.com/innovation/Hypothesize-That 2025-08-04T10:18:01+02:00 0.5 https://www.ucb.com/solutions/digital-care-transformation 2025-12-19T15:08:48+01:00 0.5 https://www.ucb.com/solutions/digital-care-transformation/immunology 2025-08-12T13:27:59+02:00 0.5 https://www.ucb.com/solutions/digital-care-transformation/neurology 2025-08-12T13:20:46+02:00 0.5 https://www.ucb.com/solutions/digital-care-transformation/startup-program 2025-08-20T15:17:37+02:00 0.5 https://www.ucb.com/solutions/diseases/epilepsy-and-rare-syndromes/more-than-seizures 2025-10-28T14:01:54+01:00 0.5 https://www.ucb.com/solutions/products/cimzia-Polyarticular-Juvenile-Idiopathic-Arthritis 2025-09-25T11:20:15+02:00 0.5 https://www.ucb.com/solutions/diseases/myasthenia-gravis/faces-of-MG 2025-10-16T08:58:24+02:00 0.5 https://www.ucb.com/solutions/diseases/myasthenia-gravis/faces-of-MG/Alisa 2025-10-16T09:05:26+02:00 0.5 https://www.ucb.com/solutions/diseases/myasthenia-gravis/faces-of-MG/Candace 2025-10-16T09:01:29+02:00 0.5 https://www.ucb.com/solutions/diseases/myasthenia-gravis/faces-of-MG/Anna 2025-10-16T09:02:19+02:00 0.5 https://www.ucb.com/solutions/diseases/myasthenia-gravis/faces-of-MG/references 2025-10-16T09:07:07+02:00 0.5 https://www.ucb.com/privacy-policies 2026-02-18T14:54:08+01:00 0.5 https://www.ucb.com/search-page 2025-12-01T13:15:35+01:00 0.5 https://www.ucb.com/solutions/diseases/hidradenitis-suppurativa/Navigating-Hidradenitis-Suppurativa-and-Motherhood 2025-12-18T16:04:14+01:00 0.5 https://www.ucb.com/investors/Integrated-annual-report-2025 2026-03-03T09:07:26+01:00 0.5 https://www.ucb.com/fy25-earnings-call-replay 2026-02-27T12:23:37+01:00 0.5 https://www.ucb.com/investors/UCB-shareholders/Shareholders-meeting-2026 2026-03-27T07:06:48+01:00 0.5 https://www.ucb.com/advantage-hers/fr/pr%C3%A9sentation-de-nouvelles-voix-de-patientes-%C3%A0-la-campagne-avantage-pour-elle 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/advantage-hers/de/neue-patientenstimmen-bei-advantage-hers 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/advantage-hers/fi/esittelyssa-advantage-hers-kampanjan-uudet-potilaat 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/advantage-hers/dk/vi-introducerer-nye-patientstemmer-for-advantage-hers 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/advantage-hers/no/introduksjon-av-nye-pasientstemmer-i-advantage-hers 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/unique-patient-led-and-co-authored-analysis-of-the-experience-of-living-with-myasthenia-gravis-published-in-neurology-and-therapy 2022-06-27T10:20:36+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares 2022-06-27T09:23:43+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-license-its-ai-technology-that-improves-identification-of-osteoporosis-to-imagebiopsy-lab 2022-06-23T05:46:48+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-0 2022-06-27T09:19:28+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/update-on-us-fda-review-of-biologics-license-application-bla-for-bimekizumab 2022-06-27T07:25:47+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-1 2022-06-27T07:19:31+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-bimzelxrv-bimekizumab-two-year-data-in-moderate-to-severe-plaque-psoriasis-presented-at-the-30th-european-academy-of-dermatology-and-venereology-eadv-congress 2022-06-27T07:21:58+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-2 2022-06-27T07:20:39+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-3 2022-06-27T07:17:57+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxrv-bimekizumab-receives-first-positive-health-technology-assessment-worldwide 2022-06-27T07:18:23+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-4 2022-06-27T07:13:42+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-wellington 2022-06-27T06:22:52+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-5 2022-06-27T07:19:35+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-commitment-to-treatment-and-management-of-epilepsy-at-the-34th-international-epilepsy-congress 2022-06-27T06:27:43+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-european-commission-approval-of-bimzelxrv-bimekizumab-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis 2022-06-27T09:31:42+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-6 2022-06-25T15:37:44+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-7 2022-06-26T03:08:16+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc 2022-06-27T09:23:54+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-two-year-data-showed-bimekizumab-maintained-high-levels-of-skin-clearance-in-patients-with-moderate-to-severe-plaque-psoriasis 2022-06-27T09:33:53+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-8 2022-06-27T09:22:18+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-9 2022-06-20T06:37:13+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/first-half-2021-with-sustainable-performance-delivering-on-ucb-s-strategy-and-guidance 2024-01-03T17:03:40+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-10 2022-06-27T09:25:46+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-11 2022-06-27T07:19:10+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-12 2024-01-03T17:00:56+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-31 2022-06-27T02:09:55+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-launch-of-nile-ai-inc-a-digital-health-company-set-to-transform-the-course-of-epilepsy 2024-01-03T17:09:30+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-changes-on-board-of-directors 2022-06-27T02:22:50+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-32 2022-06-27T12:15:48+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-community-health-fund-commits-to-50-covid-19-support-and-research-projects 2024-01-03T17:05:13+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-33 2022-06-27T12:11:21+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/the-lancet-publishes-two-phase-3-studies-detailing-bimekizumab-data-in-moderate-to-severe-plaque-psoriasis 2024-01-03T17:05:16+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-34 2022-06-27T12:14:18+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-and-microsoft-expand-collaboration-to-accelerate-drug-discovery-and-development 2024-01-03T17:13:31+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-sustaining-growth-now-and-into-the-future 2022-06-27T10:58:02+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-35 2022-06-27T12:17:13+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-36 2022-06-25T10:55:05+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-37 2022-06-27T12:18:43+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/share-repurchase-program-2021-to-cover-ucb-s-long-term-incentive-plans-for-its-employees 2022-06-27T04:35:35+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisitions-of-own-shares-and-disposals-of-own-shares-5 2022-06-27T09:53:11+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-gains-ce-mark-for-ava-connectr-a-first-in-class-electromechanical-device-for-use-with-biologic-treatment-in-rheumatology-and-dermatology 2022-06-27T12:29:16+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisitions-of-own-shares-and-disposals-of-own-shares-6 2022-06-27T05:23:23+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-completes-institutional-eurobond-offering-1 2022-06-25T22:21:12+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisitions-of-own-shares-and-disposals-of-own-shares-7 2022-06-27T06:32:20+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-ucb-sanv-2 2022-06-27T08:23:43+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisitions-of-own-shares-and-disposals-of-own-shares-8 2022-06-27T06:24:29+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-ucb-sanv-3 2022-06-27T12:30:19+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisitions-of-own-shares-and-disposals-of-own-shares-9 2022-06-27T05:32:14+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/notice-of-early-redemption-eu350-million-eu-1875-fixed-rate-notes-due-2-april-2022 2022-06-27T09:21:53+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-new-research-at-the-73rd-american-academy-of-neurology-annual-meeting-to-demonstrate-broad-neurology-leadership-and-future-portfolio 2024-01-03T17:02:21+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisitions-of-own-shares-and-disposals-of-own-shares-10 2022-06-27T04:29:56+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-zilucoplan-shows-no-relevant-effect-in-immune-mediated-necrotizing-myopathy-imnm 2022-06-27T10:50:59+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/the-new-england-journal-of-medicine-publishes-results-from-two-bimekizumab-phase-3-studies-in-moderate-to-severe-plaque-psoriasis 2022-06-27T10:17:18+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-present-12-abstracts-on-bimekizumab-at-aad-vmx-2021 2022-06-26T12:07:33+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisitions-of-own-shares-and-disposals-of-own-shares-11 2022-06-27T05:25:36+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-pdufa-date-for-bimekizumab 2022-06-27T10:17:05+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-general-meeting-of-shareholders-2021 2022-06-27T02:20:32+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-38 2022-06-27T10:12:45+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-39 2022-06-27T10:14:18+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/eular-2021-new-data-from-ucb-s-rheumatology-portfolio-demonstrates-real-world-value-for-patients-with-axspa-psa-and-women-of-childbearing-age 2022-06-27T10:57:22+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-40 2022-06-27T10:16:23+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-41 2022-06-27T10:18:39+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-42 2022-06-27T05:40:24+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-positive-chmp-opinion-recommending-approval-of-bimzelxr-bimekizumab-in-the-eu-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis 2022-06-27T10:25:16+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-43 2022-06-27T10:14:39+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-44 2022-06-27T10:13:11+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-45 2022-06-27T10:13:38+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-46 2024-01-03T17:01:21+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-47 2022-06-27T10:16:06+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/positive-top-line-results-from-bimzelxrvbimekizumab-phase-3-psoriatic-arthritis-study-demonstrated-significant-improvements-in-joint-and-skin-symptoms 2022-06-27T09:26:54+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-48 2024-01-03T16:58:22+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-49 2022-06-24T08:55:28+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-and-chiesi-enter-global-license-agreement-for-zampilimab-a-novel-monoclonal-antibody-for-fibrotic-lung-diseases 2022-06-27T08:30:04+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-global-partnership-to-bring-disease-modifying-therapies-to-people-living-with-parkinson-s-disease 2022-06-27T03:44:55+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-present-new-data-at-the-american-epilepsy-society-75th-annual-meeting-2021-reinforcing-long-standing-commitment-to-advancing-epilepsy-treatment-and-care 2022-06-27T08:20:17+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-50 2022-06-24T08:56:18+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-positive-phase-3-results-for-rozanolixizumab-in-generalized-myasthenia-gravis 2022-06-27T08:33:54+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/positive-top-line-results-for-bimzelxrvbimekizumab-in-phase-3-ankylosing-spondylitis-trial 2022-06-26T10:44:41+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-51 2022-06-27T08:25:37+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-52 2022-06-27T08:32:00+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-53 2022-06-27T08:19:20+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/positive-top-line-results-for-bimzelxrvbimekizumab-in-phase-3-non-radiographic-axial-spondyloarthritis-study 2022-06-27T08:29:01+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-acquire-zogenix 2022-06-27T01:16:11+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/positive-top-line-results-for-bimzelxrvbimekizumab-in-second-phase-3-psoriatic-arthritis-study 2022-06-27T04:53:39+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-54 2022-06-27T04:43:00+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-approved-in-japan-for-the-treatment-of-plaque-psoriasis-generalized-pustular-psoriasis-and-psoriatic-erythroderma 2022-06-27T04:52:36+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-55 2022-06-27T04:38:05+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-commences-tender-offer-to-acquire-zogenix-inc 2022-06-27T04:46:17+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-positive-chmp-opinion-recommending-approval-of-briviactr-brivaracetam-and-vimpatr-lacosamide-in-the-eu-for-partial-onset-seizures-in-pediatric-patients-from-two-to-four-years 2022-06-27T04:47:46+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-2 2022-06-27T04:51:46+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-positive-data-in-myasthenia-gravis-with-zilucoplan-phase-3-study-results 2022-06-27T10:17:46+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-56 2022-06-27T04:43:54+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-11 2024-01-03T16:57:10+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-12 2024-01-03T16:57:18+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/2021-delivering-on-ucb-s-strategy-and-commitments 2022-06-26T22:52:09+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-13 2022-06-25T16:44:03+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-extension-of-tender-offer-to-acquire-zogenix-inc 2022-06-25T16:39:21+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-expiration-of-hart-scott-rodino-waiting-period-for-proposed-acquisition-of-zogenix-inc 2022-06-24T08:57:16+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-completes-acquisition-of-zogenix-inc 2022-06-26T16:02:02+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-14 2022-06-26T01:28:24+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-expands-innovation-footprint-with-new-state-of-the-art-gene-therapy-facility 2022-06-26T03:19:06+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposals-of-own-shares-57 2022-06-27T01:17:34+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-15 2022-06-24T08:54:34+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-3 2022-06-26T11:28:27+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/wco-iof-esceo-2022-post-hoc-analysis-on-the-proportion-of-patients-treated-with-evenityr-vromosozumab-reaching-surrogate-threshold-effect-that-predicts-fracture-risk-reduction 2022-06-26T12:20:16+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-ucb-data-analysis-adds-to-demonstrated-efficacy-of-romosozumabv-to-reduce-the-risk-of-fractures 2022-06-25T07:46:29+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-16 2022-03-25T20:07:08+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-long-term-complete-skin-clearance-data-for-bimzelxrv-bimekizumab-in-moderate-to-severe-plaque-psoriasis-presented-at-the-2022-aad-annual-meeting 2022-03-26T15:40:43+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/us-fda-approves-finteplar-vfenfluramine-oral-solution-for-treatment-of-seizures-associated-with-lennox-gastaut-syndrome-lgs 2024-01-03T17:16:39+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-strength-of-broad-neurology-portfolio-at-74th-american-academy-of-neurology-aan-annual-meeting 2022-04-01T07:11:28+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-17 2022-04-01T20:07:53+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-18 2022-04-11T20:07:38+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-19 2022-04-15T20:07:34+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-20 2022-04-22T20:06:42+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-general-meeting-of-shareholders-2022 2022-04-28T18:10:58+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/jama-neurology-publishes-phase-3-study-results-on-the-efficacy-and-safety-of-finteplarvfenfluramine-oral-solution-for-the-treatment-of-seizures-associated-with-lennox-gastaut-syndrome-lgs 2022-05-02T19:12:13+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-efficacy-and-safety-results-for-zilucoplan-and-rozanolixizumab-in-generalized-myasthenia-gravis 2022-05-10T07:17:58+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/update-on-us-fda-review-of-biologics-license-application-bla-for-bimekizumab-0 2022-05-13T08:19:04+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-21 2022-05-13T20:07:15+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-wellington-2 2022-05-18T18:14:24+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-22 2022-05-20T20:05:31+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-first-detailed-data-from-two-phase-3-bimekizumab-studies-in-psoriatic-arthritis-to-be-presented-at-eular-2022 2022-05-23T08:40:22+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/first-presentations-of-phase-3-data-for-bimekizumab-across-the-full-spectrum-of-axial-spondyloarthritis-to-be-shared-at-eular-2022 2022-05-23T08:45:41+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-4 2022-05-24T20:14:20+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-5 2022-05-25T20:15:08+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-6 2022-05-25T20:19:11+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-23 2022-06-02T20:05:59+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-24 2022-06-10T20:07:01+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-25 2022-06-17T20:06:43+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-updates-financial-guidance-for-2022-while-maintaining-2025-financial-guidance 2022-06-24T07:15:49+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-26 2022-06-24T20:07:29+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/share-repurchase-program-2022-to-cover-ucb-s-long-term-incentive-plans-for-employees 2022-06-24T20:20:15+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-27 2024-01-03T16:57:41+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-and-disposal-of-own-shares 2024-01-03T17:04:54+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-and-disposal-of-own-shares-0 2024-01-03T17:05:40+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-and-disposal-of-own-shares-1 2022-07-15T20:14:50+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-and-disposal-of-own-shares-2 2022-07-20T20:13:34+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/strong-first-six-months-ucb-with-continued-delivery-and-strong-resilience 2022-07-28T07:17:36+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-28 2022-08-05T20:06:59+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-7 2022-08-05T20:21:10+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-29 2022-08-19T20:09:51+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-strength-of-the-expanding-dermatology-portfolio-at-the-31st-eadv-congress 2022-09-01T07:08:48+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-three-year-bimzelxrv-bimekizumab-data-reinforce-long-term-maintenance-of-complete-skin-clearance-in-moderate-to-severe-plaque-psoriasis 2022-09-07T07:10:56+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/asbmr-2022-3d-modelling-of-hip-dxa-scans-in-postmenopausal-women-with-osteoporosis-reveals-superior-improvements-in-bone-density-of-romosozumab-versus-controls 2022-09-09T07:13:35+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-30 2022-09-09T20:06:58+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/european-medicine-agency-accepts-marketing-authorization-applications-for-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis 2022-09-20T07:26:47+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-latest-data-from-generalized-myasthenia-gravis-portfolio-at-aanem-meeting 2024-01-03T17:01:26+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/disposal-of-own-shares-31 2022-09-23T20:05:08+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/finteplarv-fenfluramine-approved-in-japan-for-the-treatment-of-seizures-associated-with-dravet-syndrome 2022-09-27T07:14:16+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-positive-preliminary-results-for-major-brivaracetam-briviactr-study-in-asia 2022-10-13T11:39:06+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-reinforces-commitment-to-rheumatology-with-15-abstracts-including-new-late-breaking-data-at-acr-convergence-2022 2022-11-08T18:09:31+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimekizumab-demonstrated-sustained-clinical-responses-to-week-52-in-phase-3-studies-in-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis 2022-11-10T07:14:19+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-us-fda-acceptance-of-new-drug-application-and-ema-maa-validation-for-zilucoplan-for-the-treatment-of-generalized-myasthenia-gravis-in-adult-patients 2022-11-14T07:17:11+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-submits-response-to-fda-complete-response-letter-for-bimekizumab 2024-01-03T17:07:46+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-present-data-at-the-american-epilepsy-society-76th-annual-meeting-2022-supporting-a-decades-long-commitment-to-transforming-epilepsy-care 2022-12-01T07:12:37+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-and-disposal-of-own-shares-3 2022-07-01T20:05:37+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/the-lancet-publishes-results-from-two-bimekizumab-phase-3-studies-in-psoriatic-arthritis 2022-12-07T06:15:24+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-positive-phase-3-studies-for-bimekizumab-in-hidradenitis-suppurativa 2022-12-09T06:14:50+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/changes-in-ucb-s-board-of-directors-1 2022-12-12T17:18:10+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-and-praxis-precision-medicines-announce-epilepsy-research-collaboration 2022-12-13T21:18:31+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/finteplarv-fenfluramine-oral-solution-recommended-for-approval-in-the-eu-for-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome-lgs 2022-12-19T06:38:52+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-fda-acceptance-of-bla-resubmission-for-bimekizumab 2022-12-23T06:16:14+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-rozanolixizumab-bla-for-the-treatment-of-generalized-myasthenia-gravis-filed-with-us-fda-and-designated-for-priority-review 2023-01-06T06:19:15+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-financial-update 2024-01-03T17:08:09+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/annals-of-the-rheumatic-diseases-publishes-results-from-two-bimekizumab-phase-3-studies-in-axial-spondyloarthritis 2023-01-18T06:11:53+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/finteplarv-fenfluramine-oral-solution-approved-in-the-eu-for-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome-lgs 2023-02-08T06:17:16+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-managed-2022-headwinds-and-is-ready-for-2023-launches 2023-02-22T06:13:38+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/share-repurchase-program-2023-to-cover-ucb-s-long-term-incentive-plans-for-employees 2023-02-24T19:15:09+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-20 2023-03-03T19:14:55+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-board-of-directors-appoints-jonathan-peacock-as-new-chair 2023-03-09T06:26:01+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/cancer-research-uk-signs-multi-project-collaboration-with-ucb-to-advance-oncology-antibody-candidates 2023-03-09T06:29:43+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-21 2023-03-10T19:14:49+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/aitia-and-ucb-announce-strategic-drug-discovery-collaboration-in-huntington-s-disease 2024-01-03T17:07:49+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-present-eight-bimekizumab-abstracts-at-aad-2023-with-results-from-studies-in-psoriasis-psoriatic-arthritis-and-hidradenitis-suppurativa 2023-03-16T06:12:46+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-22 2023-03-17T19:14:28+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimekizumab-phase-3-data-in-hidradenitis-suppurativa-show-clinically-meaningful-deep-and-maintained-response-over-48-weeks 2023-03-18T18:34:02+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-23 2023-03-24T19:13:32+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-rozanolixizumab-and-zilucoplan-phase-3-generalized-myasthenia-gravis-studies-published-in-prestigious-the-lancet-neurology-journal 2023-04-13T05:14:29+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-strength-and-depth-of-neurology-portfolio-at-75th-american-academy-of-neurology-aan-annual-meeting 2023-04-20T05:12:12+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-positive-chmp-opinions-for-bimekizumab-for-the-treatment-of-adults-with-psoriatic-arthritis-and-axial-spondyloarthritis-in-the-european-union 2023-04-27T05:11:31+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-general-meeting-of-shareholders-2023 2024-01-03T17:11:47+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-and-ariceum-therapeutics-sign-a-strategic-research-collaboration-to-discover-new-modalities-for-the-treatment-of-immune-related-diseases-and-cancer 2023-05-11T05:44:15+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-and-veeva-collaborate-to-advance-the-patient-experience-in-clinical-trials 2024-01-03T17:02:50+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-8 2023-05-26T18:16:47+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-commitment-to-advancing-care-in-immune-mediated-inflammatory-diseases-with-23-abstracts-at-eular-2023 2023-05-30T05:10:14+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-long-term-data-on-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis-presented-at-eular-2023 2023-05-31T05:12:53+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-new-european-commission-approvals-for-bimzelxrvbimekizumab-for-the-treatment-of-psoriatic-arthritis-and-axial-spondyloarthritis 2023-06-07T05:21:16+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-commitment-to-transforming-outcomes-for-people-living-with-epilepsy-and-rare-epileptic-syndromes-at-european-pediatric-neurology-society-epns-annual-congress 2023-06-20T05:09:28+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/change-in-ucb-s-executive-committee-0 2023-06-26T12:15:28+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-provides-update-on-us-fda-review-of-the-biologics-license-application-for-bimekizumab 2024-01-03T17:08:46+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-us-fda-approval-of-rystiggor-rozanolixizumab-noli-for-the-treatment-of-adults-with-generalized-myasthenia-gravis 2024-01-03T17:35:14+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-latest-data-from-generalized-myasthenia-gravis-portfolio-at-9th-congress-of-the-european-academy-of-neurology-ean-meeting 2023-06-30T16:41:17+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-eu-regulatory-filing-for-bimekizumab-for-the-treatment-of-moderate-to-severe-hidradenitis-suppurativa 2023-07-18T05:15:32+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-now-at-the-inflection-point-ready-to-start-a-new-phase-of-growth 2023-07-27T05:15:49+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-new-data-at-35th-international-epilepsy-congress-iec-highlighting-important-advancements-across-finteplarvfenfluramine-oral-solution-and-broader-epilepsies-portfolio 2023-08-31T05:13:55+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-chmp-positive-opinion-of-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis-in-europe 2023-09-15T14:44:54+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-provides-update-on-us-regulatory-review-of-bimekizumab 2023-09-19T21:17:38+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-approval-of-rystiggor-rozanolixizumab-and-zilbrysqr-zilucoplan-for-the-treatment-of-adult-patients-with-generalized-myasthenia-gravis-in-japan 2023-09-25T16:25:01+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-present-new-bimekizumab-data-in-hidradenitis-suppurativa-psoriasis-and-psoriatic-arthritis-at-eadv-2023 2023-10-09T05:11:51+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/phase-3-data-analysis-presented-at-eadv-2023-showed-bimekizumab-achieved-high-thresholds-of-clinical-response-in-hidradenitis-suppurativa 2023-10-12T16:15:25+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-reinforces-commitment-to-advancing-care-in-hidradenitis-suppurativa-with-six-abstracts-at-shsa-2023 2024-04-26T00:14:51+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-us-fda-approval-of-zilbrysqr-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis 2023-10-17T22:30:52+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxr-approved-by-the-us-fda-for-the-treatment-of-adults-with-moderate-to-severe-plaque-psoriasis 2023-10-18T05:51:08+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-latest-data-from-generalized-myasthenia-gravis-portfolio-at-2023-aanem-annual-meeting-and-mgfa-scientific-session 2023-11-01T06:11:32+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-launches-an-offer-to-the-public-of-6-year-520-fixed-rate-notes-in-belgium-and-in-luxembourg 2023-11-07T07:46:33+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-successfully-completes-its-offer-to-the-public-of-fixed-rate-notes-and-decides-to-early-terminate-the-subscription-period 2023-11-09T17:15:52+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-new-five-year-data-on-bimzelxrvbimekizumab-in-ankylosing-spondylitis-at-acr-convergence-2023 2023-11-10T06:12:59+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-chmp-positive-opinion-for-rozanolixizumab-for-treatment-of-adults-with-generalized-myasthenia-gravis-in-europe 2023-11-10T17:15:58+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/post-hoc-analysis-showed-meaningful-efficacy-of-certolizumab-pegol-for-ra-patients-with-high-rheumatoid-factor-rf-levels 2023-11-11T06:12:30+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/rheumacensus-experts-unite-and-call-for-essential-psoriatic-arthritis-and-axial-spondyloarthritis-care-improvements 2023-11-16T06:14:11+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-wellington-3 2023-11-23T19:13:22+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-new-data-advancing-patient-focused-scientific-leadership-at-american-epilepsy-society-annual-meeting 2023-12-01T06:14:20+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-european-commission-approval-of-zilbrysqrv-zilucoplan-for-the-treatment-of-adults-with-generalized-myasthenia-gravis 2023-12-04T06:17:40+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-receives-approval-in-japan-for-the-treatment-of-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis 2024-01-10T06:38:58+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-european-commission-approval-of-rystiggorv-rozanolixizumab-for-the-treatment-of-adults-with-generalized-myasthenia-gravis-in-europe 2024-01-08T06:21:27+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-9 2024-02-06T19:15:43+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/latest-analyses-of-bimekizumab-phase-3-studies-in-moderate-to-severe-hidradenitis-suppurativa-to-be-presented-at-ehsf-2024 2024-02-09T06:16:31+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-on-growth-path-for-a-decade-plus 2024-02-28T08:45:03+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-strategic-investment-in-imidomics-inc-to-advance-breakthrough-solutions-for-immune-mediated-inflammatory-diseases 2024-03-04T17:14:06+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimekizumab-48-week-phase-3-analyses-in-moderate-to-severe-hidradenitis-suppurativa-showed-sustained-improvements-in-skin-pain-and-draining-tunnel-count 2024-03-11T09:19:09+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/first-presentation-of-four-year-bimzelxrbimekizumab-bkzx-data-showed-long-term-maintenance-of-complete-skin-clearance-in-moderate-to-severe-plaque-psoriasis 2024-03-11T17:48:46+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-successfully-completes-institutional-eurobond-issue 2024-03-13T17:40:04+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-changes-on-board-of-directors-0 2024-03-15T17:15:59+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-positive-chmp-opinion-for-bimzelxrvbimekizumab-for-the-treatment-of-adults-with-moderate-to-severe-hidradenitis-suppurativa 2024-03-22T06:16:33+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/share-repurchase-program-2024-to-cover-ucb-s-long-term-incentive-plans-for-employees 2024-03-29T19:15:59+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/fda-accepts-supplemental-biologics-license-applications-for-bimzelxr-bimekizumab-bkzx-for-moderate-to-severe-hidradenitis-suppurativa-and-additional-2ml-device-presentations 2024-04-04T05:17:17+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-24 2024-04-05T18:13:14+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-10 2024-04-11T18:15:15+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-new-data-highlighting-developments-across-expansive-neurology-portfolio-at-76th-american-academy-of-neurology-aan-annual-meeting 2024-04-12T05:11:06+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/latest-real-world-evidence-presented-at-wco-iof-esceo-assesses-how-evenityrv-romosozumab-can-help-to-close-the-treatment-gap-in-osteoporosis 2024-04-15T09:07:16+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-25 2024-04-12T18:13:01+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/finteplarv-fenfluramine-oral-solution-approved-in-japan-for-adjunctive-treatment-of-seizures-associated-with-lennox-gastaut-syndrome-lgs 2024-04-17T05:13:52+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-26 2024-04-19T18:13:23+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-european-commission-approval-for-bimzelxrvbimekizumab-as-the-first-il-17a-and-il-17f-biologic-for-moderate-to-severe-hidradenitis-suppurativa 2024-04-22T05:17:44+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-11 2024-04-23T18:11:49+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-off-to-a-good-start-into-2024-progressing-on-its-growth-path-for-a-decade-plus 2024-04-25T05:15:52+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-general-meeting-of-shareholders-2024 2024-04-25T20:27:24+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-27 2024-04-26T18:12:36+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-28 2024-05-03T18:13:14+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-final-open-label-extension-finteplarvfenfluramine1-data-at-international-child-neurology-congress-icnc-annual-meeting 2024-05-13T16:07:00+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-29 2024-05-10T18:12:40+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-data-published-in-the-journal-of-neurology-show-clinically-meaningful-improvement-of-fatigue-in-generalized-myasthenia-gravis-gmg-with-zilbrysqrv-zilucoplan 2024-05-14T05:12:15+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-30 2024-05-17T18:12:25+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-wellington-4 2024-05-17T18:16:45+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-publication-in-the-lancet-of-phase-3-bimekizumabv-trials-in-moderate-to-severe-hidradenitis-suppurativa 2024-05-23T05:15:52+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-31 2024-05-24T18:13:27+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-positive-chmp-opinion-for-320-mg-device-presentations-of-bimzelxrv-bimekizumab 2024-05-31T09:03:56+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-32 2024-05-31T18:12:03+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-33 2024-06-07T18:13:31+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/global-experts-release-new-guidelines-on-prevention-of-progression-of-epileptic-seizures-addressing-critical-treatment-gaps 2024-06-10T05:11:28+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-share-first-presentations-of-bimzelxrv-bimekizumab-two-year-data-in-axial-spondyloarthritis-and-psoriatic-arthritis-at-eular-2024 2024-06-12T05:13:27+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-data-support-the-value-of-cimziar-for-women-living-with-chronic-rheumatic-diseases-throughout-pregnancy-and-post-partum-and-for-people-living-with-ra-and-high-rheumatoid-factor-levels 2024-06-13T05:12:59+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-34 2025-02-25T14:05:19+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-epilepsy-drug-briviactrbrivaracetam1-approved-in-japan-for-treatment-of-focal-onset-seizures 2024-06-26T05:14:47+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-spotlights-new-analyses-and-patient-insights-supporting-its-recently-launched-gmg-portfolio-at-the-10th-congress-of-the-european-academy-of-neurology-ean 2024-07-08T10:18:53+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-35 2024-06-28T18:12:01+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/strong-start-into-ucb-s-decade-of-growth 2024-07-25T05:21:10+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-european-commission-approval-for-320-mg-device-presentations-of-bimzelxrvbimekizumab 2024-08-05T05:11:55+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-goldman-sachs 2024-08-07T18:12:15+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-goldman-sachs-0 2024-08-08T18:11:33+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-goldman-sachs-1 2024-08-09T18:11:50+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-24 2024-08-21T18:12:01+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-25 2024-08-23T18:11:05+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-accelerate-innovation-and-strategic-partnerships-divesting-mature-product-portfolio-in-china 2024-08-26T05:18:57+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-26 2024-08-28T18:12:37+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-27 2024-09-02T18:11:49+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-28 2024-09-04T18:11:38+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-29 2024-09-05T18:05:48+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-30 2024-09-05T18:41:23+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-new-data-across-expansive-epilepsies-portfolio-at-15th-european-epilepsy-congress-eec 2024-09-06T05:10:58+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-31 2024-09-06T18:11:02+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-insights-highlight-unmet-needs-for-people-living-with-lennox-gastaut-syndrome-and-significant-burden-of-the-disease 2024-09-09T05:11:05+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-us-fda-approvals-for-bimzelxr-bimekizumab-bkzx-for-the-treatment-of-psoriatic-arthritis-non-radiographic-axial-spondyloarthritis-and-ankylosing-spondylitis 2024-09-23T05:21:46+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-and-biogen-announce-positive-topline-results-from-phase-3-study-of-dapirolizumab-pegol-in-systemic-lupus-erythematosus-and-are-initiating-second-phase-3-study-in-2024 2024-09-24T05:17:53+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-32 2024-09-24T18:11:48+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-new-4-year-data-for-bimzelxrvbimekizumab-in-moderate-to-severe-plaque-psoriasis-at-eadv-2024 2024-09-25T05:12:14+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-33 2024-09-25T18:11:38+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-34 2024-09-26T18:11:13+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-late-breaking-two-year-data-for-bimzelxrvbimekizumab-in-moderate-to-severe-hidradenitis-suppurativa-at-eadv-2024 2024-09-27T05:14:50+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-35 2024-09-27T18:11:17+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-a-head-to-head-study-evaluating-bimzelxrvbimekizumab-versus-skyrizir-risankizumab-in-active-psoriatic-arthritis 2024-09-30T05:17:41+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-36 2024-09-30T18:13:34+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-37 2024-10-01T18:11:25+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-38 2024-10-03T18:11:13+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-39 2024-10-09T18:12:29+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-40 2024-10-10T18:11:32+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-new-data-for-gmg-management-at-the-2024-american-association-of-neuromuscular-electrodiagnostic-medicine-aanem-annual-meeting-and-mgfa-scientific-session 2024-10-11T05:10:57+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-us-fda-approval-for-320-mg-single-injection-device-presentations-of-bimzelxr-bimekizumab-bkzx 2025-02-25T14:04:49+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-bepranemab-phase-2a-study-results-accepted-for-late-breaking-presentation-at-clinical-trials-on-alzheimer-s-disease-ctad-2024-meeting 2024-10-22T05:08:41+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-us-fda-approval-for-bimzelxr-bimekizumab-bkzx-as-the-first-il-17a-and-il-17f-inhibitor-for-adults-with-moderate-to-severe-hidradenitis-suppurativa 2024-11-20T06:09:26+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/dapirolizumab-pegol-phase-3-data-presented-at-the-american-college-of-rheumatology-shows-significant-reduction-in-systemic-lupus-erythematosus-disease-activity 2024-11-19T06:06:00+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-41 2024-11-18T19:37:07+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-42 2024-11-18T19:05:38+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-bimzelxr-bimekizumab-bkzx-data-at-acr-convergence-2024-highlights-ucb-s-efforts-to-deliver-differentiated-care-for-patients-with-psoriatic-arthritis-and-axial-spondyloarthritis 2024-11-14T17:05:29+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-43 2024-11-12T19:06:09+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-44 2024-11-08T19:05:23+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-completes-sale-of-established-brands-and-updates-2024-financial-guidance 2024-11-05T06:11:59+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-encouraging-data-on-bepranemab-in-early-alzheimer-s-disease-in-phase-2a-study-at-ctad-2024 2024-10-31T17:06:34+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-latest-scientific-research-in-epilepsy-at-american-epilepsy-society-aes-annual-meeting 2024-11-27T06:04:27+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-focuses-on-new-launch-and-completes-divestment-of-mature-product-business-in-china 2024-11-29T17:06:22+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/findings-from-minzasolmin-proof-of-concept-orchestra-study-shape-next-steps-in-ucb-parkinson-s-research-program 2024-12-16T18:09:43+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-wellington-5 2025-01-07T17:01:28+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-partners-with-ailux-biologics-a-division-of-xtalpi-on-biologics-ai-platform 2025-01-09T06:08:20+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-decade-of-growth-and-patient-value-strategy-driving-differentiated-innovation 2025-01-15T06:07:55+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/rystiggorvrozanolixizumab-for-generalized-myasthenia-gravis-gmg-receives-eu-approval-for-two-new-administration-methods 2025-01-31T06:08:28+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxrvbimekizumab-two-year-data-at-ehsf-2025-demonstrate-sustained-disease-control-in-hidradenitis-suppurativa-hs 2025-02-12T06:08:46+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/on-growth-path-for-a-decade-plus-strong-launch-execution-driving-company-growth 2025-02-27T06:22:31+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-bkzx-two-year-data-at-aad-showed-potential-to-eliminate-draining-tunnels-in-hidradenitis-suppurativa-hs-and-reduction-in-disease-burden 2025-04-07T15:41:35+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-bkzx-five-year-data-at-aad-2025-showed-sustained-skin-clearance-and-long-term-efficacy-in-moderate-to-severe-plaque-psoriasis 2025-03-10T17:44:15+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/share-repurchase-program-2025-to-cover-ucb-s-long-term-incentive-plans-for-employees 2025-03-07T19:06:37+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-45 2025-03-11T19:07:21+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-46 2025-03-12T19:06:34+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-36 2025-03-14T19:03:35+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/new-data-on-investigational-therapy-for-thymidine-kinase-2-deficiency-presented-at-muscular-dystrophy-association-mda-2025-conference 2025-03-19T06:07:44+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-37 2025-03-21T19:04:27+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-38 2025-03-28T19:03:35+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-key-data-from-alzheimer-s-and-parkinson-s-disease-research-programs-at-adpd-2025 2025-04-01T05:06:52+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-latest-research-across-leading-neurology-portfolio-at-american-academy-of-neurology-aan-meeting-2025 2025-04-03T05:06:13+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-39 2025-04-05T06:51:56+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/global-data-show-real-world-effectiveness-of-romosozumab-for-patients-at-high-fracture-risk 2025-04-11T17:49:51+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-s-general-meeting-of-shareholders-2025 2025-04-24T16:06:37+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/rystiggor-rozanolixizumab-receives-approval-in-japan-for-two-new-administration-methods-as-ucb-begins-onward-program-for-patient-support 2025-05-09T05:07:39+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-expansive-data-set-at-15th-myasthenia-gravis-foundation-of-america-mgfa-international-conference-highlighting-commitment-to-advancing-gmg-treatment-outcomes-and-experiences 2025-05-13T05:07:18+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-and-domino-data-lab-collaborate-to-modernize-statistical-computing-environment-in-life-sciences 2025-05-19T16:38:28+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxrvbimekizumab-three-year-data-at-eular-2025-showed-lasting-efficacy-and-control-of-inflammation-in-psoriatic-arthritis-and-axial-spondyloarthritis 2025-06-11T05:08:34+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/dapirolizumab-pegol-phase-3-data-in-sle-presented-at-the-annual-european-congress-of-rheumatology-eular-show-improvement-in-fatigue-and-reduction-in-disease-activit 2025-06-12T05:06:42+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-major-us-investment-to-expand-biologics-manufacturing-capacity 2026-02-20T06:12:50+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-12 2025-06-16T18:06:28+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-present-new-data-from-its-neurology-portfolio-at-the-11th-european-academy-of-neurology-ean-congress-2025 2025-06-20T16:35:40+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-positive-results-from-gemz-phase-3-study-of-fenfluramine-in-cdkl5-deficiency-disorder 2025-06-27T05:08:24+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-latest-research-advancements-at-european-pediatric-neurology-society-congress 2025-07-08T05:06:46+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-bkzx-two-year-data-at-aad-showed-potential-to-eliminate-draining-tunnels-in-hidradenitis-suppurativa-hs-and-reduction-in-disease-burden-0 2025-07-08T12:21:09+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-blackrock-inc-47 2025-07-08T18:05:00+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-13 2025-07-10T18:06:41+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/from-differentiated-innovation-to-outstanding-delivery-a-strong-first-half-performance 2025-07-31T05:21:40+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-14 2025-08-12T18:07:15+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-latest-research-and-clinical-advancement-across-leading-epilepsy-portfolio-at-international-epilepsy-congress 2025-08-29T05:05:38+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxrvbimekizumab-new-three-year-data-in-hidradenitis-suppurativa-at-eadv-showed-sustained-disease-control-across-the-most-stringent-clinical-endpoints 2025-09-17T05:14:38+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxrv-bimekizumab-data-in-moderate-to-severe-plaque-psoriasis-at-eadv-showed-four-year-sustained-remission-and-potential-to-reduce-psoriatic-arthritis-progression-risk 2025-09-17T05:08:37+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-advances-long-term-innovation-strategy-with-new-research-development-facility-at-braine-l-alleud-campus 2025-02-10T06:03:58+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-successful-first-in-patient-trial-for-galvokimig-in-moderate-to-severe-atopic-dermatitis-at-eadv 2025-09-18T05:11:46+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/transparency-notification-fmr-llc-15 2025-10-09T18:06:46+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/results-published-in-neurology-highlight-a-95-reduction-in-risk-of-death-with-pyrimidine-nucleostide-therapy-in-patients-with-thymidine-kinase-2-deficiency-tk2d 2025-10-13T05:06:05+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/final-analysis-of-open-label-extension-ole-study-of-finteplarv-fenfluramine-in-lennox-gastaut-syndrome-published-in-epilepsy-and-behavior 2025-10-17T15:42:10+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-bkzx-three-year-rheumatology-data-at-acr-2025-demonstrated-sustained-inflammation-control-in-psoriatic-arthritis-and-axial-spondyloarthritis 2025-10-25T14:06:37+02:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-to-unveil-new-data-for-rystiggorvand-zilbrysqrv-for-gmg-at-the-2025-aanem-annual-meeting-and-mgfa-scientific-session 2025-10-29T06:07:06+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxr-bimekizumab-bkzx-data-in-hidradenitis-suppurativa-showed-improvements-in-pain-and-resolution-of-draining-tunnels-sustained-to-three-years 2025-10-31T17:05:54+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/us-fda-approves-kygevvitm-doxecitine-and-doxribtimine-the-first-and-only-treatment-for-adults-and-children-living-with-thymidine-kinase-2-deficiency-tk2d 2025-11-13T09:20:56+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-strategic-executive-leadership-rotation-to-drive-future-growth-and-innovation 2025-11-06T18:40:38+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-shares-leading-scientific-research-and-advances-at-american-epilepsy-society-annual-meeting 2025-12-04T06:06:57+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-upgrades-2025-financial-guidance-based-on-strong-performance 2025-12-05T06:12:51+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-positive-results-from-gemz-phase-3-study-at-aes-showing-fenfluramine-significantly-reduces-countable-motor-seizure-frequency-in-cdkl5-deficiency-disorder 2025-12-08T06:10:01+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/innovation-and-execution-power-ucb-s-success 2026-01-13T06:13:46+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/kygevvir-doxecitine-and-doxribtimine-recommended-for-approval-in-the-european-union-as-treatment-for-thymidine-kinase-2-deficiency-tk2d 2026-01-30T12:15:18+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-showcases-three-year-hidradenitis-suppurativa-data-at-ehsf-bimzelxrvbimekizumab-achieved-inflammatory-lesion-resolution-and-substantial-disease-severity-improvements 2026-02-04T06:05:55+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/strong-execution-fueling-sustained-company-growth 2026-02-26T08:29:06+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-and-antengene-enter-global-license-agreement-for-atg-201-a-b-cell-depleting-bispecific-antibody 2026-03-03T22:04:31+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/bimzelxrvbimekizumab-superior-to-skyrizir-risankizumab-in-be-bold-first-head-to-head-study-in-active-psoriatic-arthritis-psa-to-demonstrate-superiority-in-acr50 2026-03-11T06:03:05+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/share-repurchase-program-2026-to-cover-ucb-s-long-term-incentive-plans-for-employees 2026-03-13T19:01:55+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-40 2026-03-20T19:01:19+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-selects-georgia-for-new-us-biologics-manufacturing-facility-5b-economic-impact-and-330-permanent-jobs 2026-03-24T18:47:18+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-receives-positive-chmp-opinion-for-new-zilbrysqrv-zilucoplan-pre-filled-pen-in-eu-for-adults-living-with-generalized-myasthenia-gravis 2026-03-26T06:01:05+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-annual-general-meeting-of-shareholders-2026 2026-03-27T06:00:40+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-announces-new-bimzelxr-bimekizumab-bkzx-data-at-aad-showing-durable-symptom-control-throughout-three-years-in-hidradenitis-suppurativa 2026-03-27T14:00:28+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/ucb-presents-new-bimzelxr-bimekizumab-bkzx-data-at-aad-demonstrating-high-rates-of-durable-and-complete-skin-clearance-in-moderate-to-severe-plaque-psoriasis 2026-03-27T14:05:32+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/acquisition-of-own-shares-41 2026-03-27T19:00:37+01:00 0.5 https://www.ucb.com/newsroom/press-releases/article/european-commission-approves-kygevvirv-doxecitine-and-doxribtimine-as-first-and-only-treatment-for-thymidine-kinase-2-deficiency-tk2d 2026-03-31T05:00:38+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/our-new-employee-value-proposition-making-a-mark-for-patients 2022-06-26T22:59:31+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/international-epilepsy-day-2021-reflecting-on-our-journey-and-stepping-into-the-future-of-epilepsy 2022-06-26T18:45:56+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/our-ucb-external-sustainability-advisory-board-accelerating-our-journey-to-becoming-a-sustainable-biopharma-leader 2022-06-27T00:48:02+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/digital-transformation-partnering-with-the-boston-consulting-group-and-challenging-students-to-improve-patient-care-through-digital-strategies 2022-06-26T12:46:41+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-ventures-and-axa-venture-partners-seeking-innovation-in-digital-health 2022-06-26T20:16:15+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/showing-our-stripes-ucb-s-commitment-to-the-rare-disease-community 2022-06-26T10:28:43+02:00 0.5 https://www.ucb.com/investors/magazine/detail/article/ucb-2020-financial-results-continued-growth-while-looking-to-the-future 2025-08-25T16:27:46+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/collaborating-with-microsoft-to-reinvent-how-medicines-are-made 2022-06-27T11:56:55+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/using-imaging-to-bring-the-right-treatments-to-the-right-patients-in-movement-disorders 2022-06-24T07:42:42+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/delivering-patient-value-faster-than-ever 2025-08-25T16:26:33+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/embracing-digital-business-transformation-to-accelerate-tailored-solutions-for-patients 2022-06-26T23:57:41+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/supporting-young-talent-to-shape-the-future-of-healthcare-through-innovative-digital-solutions 2022-06-25T03:04:51+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/reinventing-ucb-new-directions-new-plants-and-new-talent 2022-06-26T23:00:35+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/hackathon-brings-together-diverse-talents-for-digital-innovation 2025-08-25T16:13:33+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/join-us-in-saying-thankyoumsl-on-this-internationalmslday 2025-08-25T16:12:58+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-aan-2021-embracing-digital-knowledge-sharing-and-virtual-engagement-at-premier-global-neurology-congress 2022-06-27T09:47:16+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-at-aan-2021-a-patient-led-analysis-on-the-experience-of-living-with-mg 2022-06-26T16:42:48+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/bringing-value-to-patients-living-with-parkinson-s-disease 2022-06-26T19:47:35+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/the-ip-pact-our-commitment-to-putting-patients-at-the-heart-of-our-approach-to-ip 2022-06-24T03:21:15+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/world-as-day-enhancing-the-patient-experience-through-key-collaborations 2022-06-24T03:16:55+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/why-ucb-has-made-a-science-based-commitment-to-reducing-emissions 2022-06-26T17:31:33+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/happy-patient-happy-doctor-the-importance-of-listening-to-what-really-matters-to-patients 2025-08-25T16:11:07+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/clinical-trial-day-honoring-our-clinical-researchers 2025-08-25T16:10:39+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/ucb-celebrates-patient-strength-during-mg-awareness-month 2022-06-26T10:20:11+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/ucb-aoec-2021-our-commitment-to-women-of-childbearing-age-living-with-epilepsy 2022-06-24T03:12:15+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/our-commitment-to-changing-the-status-quo-in-psoriasis-care 2022-06-26T12:46:18+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/understanding-the-impact-of-chronic-inflammatory-diseases-on-women-update-on-research-with-patients-for-patients 2024-01-03T17:05:40+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/how-ai-is-accelerating-the-development-of-new-treatments-for-specific-patient-populations 2022-06-26T10:57:22+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/ucb-is-proud-to-partner-on-a-new-eu-research-project-hippocrates-to-improve-diagnostic-and-therapeutic-options-for-patients-living-with-psoriatic-arthritis 2024-01-03T17:05:54+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/with-more-than-90-years-of-innovation-behind-us-we-are-looking-to-the-future 2025-08-25T16:09:09+02:00 0.5 https://www.ucb.com/investors/magazine/detail/article/ucb-hy2021-financial-results-solid-performance-despite-the-pandemic-delivering-on-our-strategy-guidance 2025-08-25T16:06:36+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/evolving-the-epilepsy-treatment-paradigm 2022-06-26T12:30:09+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/creating-meaningful-partnerships-to-alleviate-the-global-burden-of-epilepsy 2022-06-24T09:04:40+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/meeting-unmet-needs-in-epilepsy-management-through-digital-health-technological-solutions 2024-01-03T17:08:22+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/ucb-s-braine-site-biopharma-s-best-kept-secret 2025-08-25T16:10:20+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/the-pursuit-of-continuous-innovation 2025-08-25T16:06:42+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/our-rd-response-to-covid-19-a-patients-first-approach 2025-08-25T16:03:57+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/using-our-innovative-antibody-know-how-to-enhance-the-power-of-nature 2025-08-25T16:02:25+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/understanding-and-recognizing-the-real-life-impact-of-little-understood-conditions-we-highlight-global-itp-awareness-week 2022-06-26T22:09:20+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/eadv-2021-shining-a-light-on-the-latest-science-in-dermatology 2022-06-26T02:00:38+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/the-art-of-being-data-enabled-ucb-s-approach-to-delivering-innovative-patient-solutions 2025-08-25T16:00:17+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/sustainable-business-growth-as-a-way-to-contribute-to-ucb-successful-future-and-prepare-a-better-world-for-generations-to-come 2025-08-25T16:00:01+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/world-psoriasis-day-2021-uniting-for-action 2022-06-25T06:17:34+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/together-we-can-make-a-difference-on-world-psoriasis-day 2022-06-26T20:59:40+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/the-gene-therapy-evolution 2025-08-25T15:55:16+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/green-is-the-new-normal-for-ucb 2025-08-25T15:52:54+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/virtual-expo-advances-ucb-s-digital-transformation-journey 2022-06-26T02:47:48+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-at-icd-2021-exploring-the-unmet-needs-of-people-living-with-psoriasis 2025-08-25T15:43:45+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/unique-patient-led-study-into-life-with-myasthenia-gravis-published-in-neurology-and-therapy 2022-06-27T02:48:01+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/partnering-with-patient-organizations-for-parkinson-s-research 2025-08-25T15:41:47+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/bringing-diverse-mindsets-together-to-meet-patient-needs 2025-08-25T15:39:59+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/unleashing-the-power-of-digital-solutions-in-epilepsy-care 2022-06-26T00:26:17+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-digital-care-transformation-dctx-incubator-partnering-in-innovations-that-positively-benefit-patients-society-and-the-world 2024-01-03T17:07:49+01:00 0.5 https://www.ucb.com/investors/magazine/detail/article/why-we-have-built-our-future-on-creating-sustainable-value-for-all-stakeholders 2024-01-03T17:06:52+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-supports-launch-of-the-iof-scope-2021-report-about-the-increasing-burden-of-osteoporosis-and-inequality-of-care-in-europe 2024-01-03T17:05:26+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/launch-of-the-dctx-innovation-incubator-partnering-in-innovations-that-positively-benefit-patients-society-and-the-world 2024-01-03T17:06:39+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/insights-that-matter-exploring-three-of-the-most-critical-trends-in-healthcare 2024-01-03T17:06:04+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/partnering-for-greater-impact-with-microsoft-in-rd 2024-01-03T17:10:18+01:00 0.5 https://www.ucb.com/investors/magazine/detail/article/2021-results-show-ucb-continues-to-innovate-for-better-health-together-delivering-on-strategy-and-commitments 2025-08-25T16:35:34+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/collaborating-with-the-patient-community-for-the-patient-community-in-mg 2025-08-25T15:39:18+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/gene-therapy-a-new-and-innovative-facility-new-capabilities-and-new-opportunities 2025-08-25T15:39:41+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/strengthening-our-commitment-for-people-living-with-epilepsy 2025-08-25T15:23:38+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-s-digital-care-transformation-dctx-incubator-announces-first-ventures 2024-01-03T17:05:45+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/new-patient-centred-framework-informs-ucb-s-approach-to-rd-drug-development-and-ensures-patients-are-at-the-heart-of-creating-our-innovative-solutions 2025-08-25T15:29:19+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-at-the-2022-aad-annual-meeting-our-commitment-to-advancing-science-in-dermatology 2025-08-25T15:19:15+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/let-s-get-digital-a-look-at-ucb-s-digital-transformation-in-rd 2025-08-25T15:20:41+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/world-parkinson-s-day-2022-a-patient-centred-model-for-parkinson-s-research 2024-01-03T17:09:13+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/two-more-ventures-join-ucb-s-digital-care-transformation-dctx-incubator 2024-01-03T17:07:33+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-at-ects-2022-highlighting-solutions-to-meet-the-needs-of-people-living-with-osteoporosis 2024-10-22T16:56:18+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-launches-digital-health-roundtable-series 2024-01-03T17:06:29+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/our-new-code-of-conduct-putting-ucb-s-ethics-into-action-to-help-employees-navigate-complexity-and-support-decision-making 2024-01-03T17:04:26+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/piloting-wearable-sensor-technologies-for-clinical-trials 2024-01-03T17:06:26+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/eular-2022-ucb-unites-with-the-community-to-share-the-latest-scientific-breakthroughs-and-clinical-research-in-rheumatology 2025-08-25T15:15:46+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/celebrating-the-hybrid-experience-at-the-13th-international-immunology-summit-2022 2024-01-03T17:04:30+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/hacking-agile-project-management-to-unlock-greater-patient-value 2025-08-25T15:11:34+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/supporting-hidradenitis-suppurativa-hs-awareness-week 2025-08-25T15:20:01+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/pioneering-new-and-innovative-approaches-to-drug-discovery 2024-01-03T17:06:53+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/medcomms-day-2022-celebrating-our-global-medical-writing-team 2025-08-25T15:10:07+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/today-marks-international-dravet-syndrome-awareness-day 2024-01-03T17:05:05+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/dctx-incubator-a-pathway-to-innovation-driven-by-purpose 2024-01-03T17:08:19+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-is-a-proud-sponsor-of-spin-2022 2024-01-03T17:03:55+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/capturing-meaningful-patient-experiences-in-parkinson-s-research 2024-01-03T17:05:58+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/capturing-real-world-data-and-evidence-in-clinical-trials 2024-01-03T17:06:51+01:00 0.5 https://www.ucb.com/investors/magazine/detail/article/ucb-hy2022-financial-results-strong-performance-resilience-and-delivery 2024-01-03T17:07:01+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/dctx-team-working-hand-in-hand-with-epihunter 2024-01-03T17:04:21+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/looking-forward-to-an-exceptional-eadv-2022-experience 2024-01-03T17:05:57+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/ucb-proud-to-mark-tk2dtuesday-and-recognize-challenges-and-unmet-needs-faced-by-families-living-with-tk2d 2024-01-03T17:06:32+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/partnering-with-patients-to-innovate-where-it-matters 2024-01-03T17:02:04+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/belgium-a-home-for-innovation 2024-01-03T17:06:02+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/world-osteoporosis-day-2022-question-fractures-more 2024-10-22T17:27:45+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/we-embrace-collaboration 2024-01-03T17:06:14+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-at-ffn-2022-taking-a-united-stance-on-the-importance-of-post-fracture-care 2024-01-03T17:03:05+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/innovative-tech-at-the-heart-of-ucb 2025-08-25T15:06:48+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/uniting-with-the-community-for-world-psoriasis-day-2022 2024-01-03T17:04:16+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/international-lgs-awareness-day 2024-01-03T17:07:21+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/what-is-innovation 2025-08-25T15:09:04+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/moving-the-conversation-forward-in-rheumatology-ucb-at-acr-convergence-2022 2025-08-25T15:05:30+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/energize-a-collaborative-step-forward-to-protecting-the-planet 2025-08-25T15:01:21+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/digital-transformation-how-technologies-and-digital-innovation-help-us-make-a-meaningful-impact-to-people-living-with-rheumatic-diseases 2024-01-03T17:06:07+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/culture-is-critical-when-creating-an-environment-where-innovation-thrives 2024-01-03T17:11:02+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/advancing-innovation-in-dermatology-with-collaborative-partnerships 2024-01-03T17:12:19+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-s-first-digital-health-incubator-demo-day 2024-01-03T17:06:58+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-at-aes-2022-why-30-years-in-epilepsy-are-just-the-beginning 2024-01-03T17:03:25+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/ucb-a-home-for-innovation 2024-01-03T17:11:55+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/putting-patients-first-how-ucb-ensure-that-innovation-in-science-meets-real-needs 2024-01-03T17:09:21+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/invention-vs-innovation-the-importance-of-incremental-change 2024-01-03T17:11:08+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/time-to-focus-on-hidradenitis-suppurativa 2024-01-03T17:08:03+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/innovation-and-failure-it-s-a-healthy-relationship 2025-08-25T14:27:21+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/epilepsy-facts-vs-myths 2024-01-03T17:04:52+01:00 0.5 https://www.ucb.com/investors/magazine/detail/article/ucb-successfully-navigated-the-challenges-of-2022-and-is-now-set-for-an-exciting-launch-year 2025-08-25T14:21:03+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/harnessing-the-power-of-digital-technology-to-drive-innovation 2024-01-03T17:14:43+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/prioritizing-awareness-and-access-for-people-living-with-a-rare-disease 2024-01-03T17:09:42+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/embracingequity-in-clinical-trials-for-pregnant-and-breastfeeding-women-living-with-chronic-diseases 2025-08-25T14:26:16+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/working-collaboratively-drives-innovation-and-delivers-value-for-patients 2025-08-25T14:19:09+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/exploring-the-future-of-dermatology-at-aad-2023 2025-08-25T14:19:54+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/healthcare-innovation-more-than-just-a-eureka-moment 2025-08-25T14:15:52+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/discovery-to-design-to-delivery-how-patients-are-helping-us-innovate 2025-08-25T14:16:30+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-launches-new-podcast-series-in-time-for-ects-2023-fragility-fracture-in-focus 2024-01-03T17:04:37+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/pediatric-digital-measurement-in-clinical-development 2024-01-03T17:05:44+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/human-centred-clinical-trials-driving-increased-participation 2024-01-03T17:05:12+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/aan-2023-a-unique-opportunity-to-connect-with-the-global-neurology-community 2024-01-03T17:07:25+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/our-hope-for-parkinson-s-research 2024-01-03T17:09:30+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/listen-now-to-ucb-s-fragility-fractures-in-focus-podcast-on-spotify-episode-two-marks-the-start-of-wco-iof-esceo-2023 2024-10-22T17:29:31+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/building-a-culture-of-innovation-fostering-inclusivity-and-wellbeing-in-teams 2024-01-03T17:03:36+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/transforming-rheumatology 2024-01-03T17:09:34+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-at-the-1st-international-societies-for-investigative-dermatology-isid-meeting 2025-08-25T14:14:54+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/international-clinical-trials-day-a-chance-to-debate-the-future-of-innovation 2025-08-25T14:16:37+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/clinical-trials-day-2023-strategic-approaches-in-pregnancy-and-breastfeeding-time-for-a-paradigm-shift 2024-10-30T09:49:24+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/collaboration-value-and-risk-vital-ingredients-for-healthcare-innovation 2025-08-25T14:11:48+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/patients-partnerships-and-innovation-exploring-the-future-of-rheumatology-at-eular-2023 2024-01-03T17:06:55+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/harnessing-knowledge-and-partnership-to-improve-lives-of-people-living-with-myasthenia-gravis 2024-01-03T17:08:44+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/disease-modification-in-epilepsies-key-questions-answered 2024-01-03T17:07:06+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/uniting-with-the-community-in-recognition-of-hidradenitis-suppurativa-awareness-week 2024-01-03T17:05:18+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/we-commit-to-accelerate-our-climate-target-toward-net-zero 2024-01-03T17:10:09+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/new-approaches-in-epilepsy-research 2024-01-03T17:12:58+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/innovation-in-healthcare-the-power-of-collaborations 2025-08-25T14:11:35+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/do-advances-in-clinical-trial-diversity-go-far-enough-for-women 2024-01-03T17:06:40+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/understanding-more-about-the-lived-experiences-of-people-living-with-myasthenia-gravis 2024-01-03T17:06:27+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/the-transformative-role-of-statistics-in-the-era-of-digital-technologies-and-big-data 2025-08-25T14:09:17+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/patient-involvement-in-early-parkinson-s-research 2024-01-03T17:04:43+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/we-are-prioritising-innovation-in-healthcare 2024-01-03T17:07:18+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-partnership-with-the-royal-society-of-chemistry-showcased-at-annual-conference 2025-08-25T14:01:11+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/closing-the-gap-between-the-scientist-and-the-patient 2025-08-25T13:58:55+02:00 0.5 https://www.ucb.com/investors/magazine/detail/article/half-year-report-achieving-an-inflection-point-and-embarking-on-a-new-growth-phase 2025-08-25T13:57:39+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-welcomes-the-epilepsy-treatment-updates-to-the-who-model-list-of-essential-medicines 2024-01-03T17:06:53+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/driving-innovation-and-impactful-changes-at-ucb 2025-08-25T13:56:54+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/what-is-different-for-women-living-with-epilepsy 2024-01-03T17:10:53+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/ucb-s-commitment-to-innovation-in-healthcare 2025-08-25T13:57:38+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/committed-to-drug-discovery-innovation 2025-08-25T13:57:23+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/empowering-women-s-health-at-rheumapreg-2023-conference 2024-01-03T17:08:44+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-rounds-off-fragility-fractures-in-focus-podcast-series-with-two-bone-health-congresses-ffn-asbmr 2024-01-03T17:07:38+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/transformative-partnerships-ucb-s-patient-centric-approach-to-advancing-healthcare 2024-01-03T17:07:50+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/our-bold-ambition-for-severe-neurological-diseases 2024-01-03T17:05:57+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/the-vital-role-of-patient-advocacy-groups-in-navigating-rare-and-complex-epilepsies 2025-08-25T12:14:06+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/creating-value-for-patients-through-scientific-excellence-exploring-the-future-of-dermatology-at-eadv-2023 2024-01-03T17:06:08+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/sudden-unexpected-death-in-epilepsy-our-commitment-to-supporting-families-and-patients 2025-08-25T12:08:14+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/ucb-innovation-in-business-technology-and-science 2025-08-25T12:07:31+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/evolving-expectations-for-dermatological-conditions 2024-01-03T17:05:20+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/empowering-hope-ucb-australia-s-commitment-to-childhood-epilepsy-research 2024-01-03T17:07:21+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/world-psoriasis-day-2023-let-s-unite-for-action 2024-01-03T17:08:53+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/encouraging-innovation-ucb-s-culture-of-connection-and-collaboration 2024-01-03T17:08:19+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-go-under-the-skin-with-new-hidradenitis-suppurativa-hs-podcast 2024-01-03T17:08:03+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-s-incubator-program-2023-a-look-through-our-innovative-digital-health-startups 2024-01-03T17:10:01+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/redefining-the-standard-of-care-to-meet-the-needs-of-women-with-rheumatic-diseases 2024-01-03T17:06:42+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-s-new-supplier-recognition-program-a-commitment-to-environmental-responsibility 2024-01-03T17:07:21+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/bridge-empowering-women-with-chronic-diseases-before-during-and-after-pregnancy 2024-01-03T17:11:39+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/epilepsy-awareness-month-increasing-knowledge-support-and-advocacy 2024-06-25T10:09:10+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/a-culture-of-patient-centered-healthcare-innovation 2024-01-03T17:12:01+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/cultivating-a-patient-centered-approach-to-epilepsy-research 2024-01-03T17:08:46+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/empowering-women-of-childbearing-age-a-patient-hcp-multidisciplinary-collaboration-to-enhance-care-for-wocba 2024-01-03T17:11:16+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/advancing-patient-focused-scientific-leadership-at-american-epilepsy-society-annual-meeting 2024-01-03T17:07:06+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucbcares-the-human-touch 2024-02-29T16:12:47+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/we-are-ucb-and-we-are-driven-by-science 2024-02-29T16:09:07+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/building-trust-the-crucial-bridge-between-ai-and-healthcare 2024-02-29T15:57:04+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/closing-the-knowledge-gap-including-pregnant-and-breastfeeding-individuals-in-clinical-trials 2024-02-29T16:01:59+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-community-health-fund-s-ongoing-impact-in-2024 2024-02-29T15:49:38+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-looks-forward-to-joining-the-hs-community-at-ehsf2024 2025-08-25T11:35:28+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/seizing-the-opportunity-and-uniting-for-change-international-epilepsy-day-2024 2024-10-22T17:28:47+02:00 0.5 https://www.ucb.com/investors/magazine/detail/article/2023-financial-results-on-our-way-to-deliver-growth-for-a-decade-plus-with-5-drivers-of-growth 2025-08-25T16:37:13+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/working-alongside-the-rare-disease-community-to-enhance-access-and-elevate-the-patient-voice 2024-02-29T11:13:54+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/innovating-and-collaborating-in-immuno-dermatology-a-dialogue-with-ucb-s-simon-lucas-camille-lee 2025-08-25T11:33:31+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/international-women-s-day-2024-inspiring-inclusion 2024-03-07T14:50:44+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/looking-ahead-embracing-collaboration-and-shared-learnings-at-changenow-on-25-march 2025-08-25T11:24:50+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/broadening-global-access-to-epilepsy-treatment 2024-03-22T15:11:07+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/why-don-t-all-patients-respond-to-treatment 2024-03-27T11:28:07+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/swift-action-the-importance-of-rapid-and-early-seizure-termination-rest 2024-05-14T10:46:52+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/closing-the-gap-in-osteoporosis-it-s-make-or-break-for-post-fracture-care 2025-08-25T11:25:15+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/world-parkinson-s-day-why-the-urgency-for-innovation-grows-greater-every-year 2024-04-24T15:00:24+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/advocating-for-change-in-the-lives-of-people-with-hidradenitis-suppurativa 2024-04-12T13:34:40+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/pioneering-innovation-fueling-growth-ucb-s-commitment-to-delivering-differentiated-solutions 2024-05-02T17:15:48+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/intellectual-property-ip-is-our-chance-to-drive-positive-change 2024-04-26T12:07:28+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/world-as-day-2024-spotlighting-the-signs-and-symptoms-of-axial-spondyloarthritis-axspa-how-ucb-works-with-the-axspa-community 2024-05-03T15:31:11+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/making-a-difference-together-first-ucb-pan-european-meeting-on-developmental-and-epileptic-encephalopathies-dees 2024-05-21T15:42:54+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/the-hidradenitis-suppurativa-hs-patient-partnership-summit-empowering-voices-uniting-community 2024-05-21T15:34:22+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/championing-a-future-of-hope-in-rare-disease-ucb-s-aspire4rare-vision 2025-08-22T17:15:44+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/ucb-s-commitment-to-innovation-in-drug-development 2024-05-29T14:02:06+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/reflections-on-winning-the-made-with-patients-award-our-journey-in-parkinson-s-disease 2025-08-22T17:41:03+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/hidradenitis-suppurativa-raising-awareness-championing-advocacy-and-advancing-care 2024-05-30T11:21:43+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/turning-awareness-into-action-for-myasthenia-gravis-awareness-month 2025-08-22T17:15:26+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/eular-2024-collaboration-and-innovation-to-transform-rheumatology 2024-06-10T15:13:54+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/innovating-in-epilepsy 2024-06-14T16:41:56+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/supporting-international-cdkl5-day 2024-06-17T13:28:14+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-supports-international-dravet-syndrome-awareness-day 2025-08-22T17:13:07+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-joins-the-dermatology-community-for-ifpaconference2024 2024-06-27T11:02:56+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/embracing-patient-centered-research-the-transformative-power-of-partnership 2025-08-22T17:10:24+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/shaping-a-better-future-for-women-living-with-epilepsy 2025-08-22T17:09:24+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/leading-in-healthcare-innovation-fastrax-is-on-a-mission-to-transform-the-rheumatic-disease-journey 2024-08-21T15:12:35+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/advancing-our-gene-therapy-journey 2024-07-12T10:47:43+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/preventing-the-progression-of-epileptic-seizures-and-addressing-critical-treatment-gaps 2024-07-16T15:21:43+02:00 0.5 https://www.ucb.com/investors/magazine/detail/article/half-year-results-2024-strong-start-into-ucb-s-decade-of-growth 2024-07-25T08:48:23+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/advancements-in-epilepsy-research 2025-08-22T17:14:43+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/paving-a-better-future-for-people-living-with-lennox-gastaut-syndrome 2025-08-22T16:58:10+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/healthcare-innovation-ucb-and-ku-leuven-s-collaborative-approach 2025-08-22T17:06:34+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/redefining-immunology-care-our-pledge-to-patients-and-the-healthcare-community 2025-08-22T17:05:14+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-at-eadv-2024-committed-to-advancing-care-in-immuno-dermatology 2024-09-25T09:26:38+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/asbmr-annual-meeting-2024-overview-prioritizing-patient-centered-care 2025-08-22T17:00:16+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/broadening-global-access-to-epilepsy-treatment-an-update-from-rwanda 2024-10-09T17:01:34+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/world-arthritis-day-2024-informed-choices-better-outcomes 2024-10-11T13:41:06+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/ucb-s-commitment-to-understanding-sudden-unexpected-death-in-epilepsy 2025-08-22T16:50:16+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/delivering-medicines-and-innovation-ucb-clearpoint-neuro-s-partnership 2024-12-10T14:18:46+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/ucb-belgium-a-global-hub-of-healthcare-innovation 2024-12-10T13:53:54+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/moms-really-can-do-it-all-meet-tracy-a-mom-caregiver-neuroscientist-and-advocate-in-the-rare-disease-community 2025-08-22T16:47:58+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/world-psoriasis-day-2024-celebrating-the-invaluable-role-of-family 2024-11-22T10:02:25+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/advancing-rheumatology-research-ucb-at-acr-convergence-2024 2024-11-22T10:03:25+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/closing-gaps-in-hs-care-through-community-engagement-and-scientific-innovation 2024-11-22T10:08:38+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/exciting-updates-to-ucb-s-corporate-website-wwwucbcom 2024-11-27T14:54:41+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-net-zero-targets-validated-by-the-science-based-targets-initiative-a-critical-step-in-our-sustainability-agenda 2024-11-28T13:54:59+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/what-does-the-future-look-like-for-rare-genetic-epilepsies 2025-08-22T14:28:00+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/ucb-and-ailux-biologics-join-forces-to-transform-biologics-research 2025-01-09T15:01:23+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/driving-innovation-forward-ucb-unveils-new-rd-facility 2025-02-10T13:29:15+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/more-than-you-can-imagine-shedding-light-on-the-burden-of-rare-epilepsies 2025-02-10T11:48:47+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/ucbcaresr-a-decade-of-support-and-beyond 2025-02-12T11:15:23+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/coming-soon-hypothesize-that-a-new-science-podcast-from-ucb 2025-08-22T14:29:30+02:00 0.5 https://www.ucb.com/investors/magazine/detail/article/strong-launch-execution-driving-company-growth 2025-02-27T13:19:24+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/collaboration-and-innovation-drives-realised-project-to-change-the-paradigm-for-clinical-trials-in-rare-and-ultra-rare-diseases 2025-02-28T15:58:34+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/exploring-the-future-of-immuno-dermatology-care-ucb-at-aad-annual-meeting-2025 2025-08-22T14:22:09+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/international-women-s-day-2025-accelerate-action 2025-03-10T11:53:55+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/our-commitment-to-advancing-treatments-for-tk2d 2025-03-18T09:12:45+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/data-driven-federated-learning-in-drug-discovery-with-knowledge-distillation 2025-03-19T12:00:36+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/innovating-in-neurology-ucb-s-commitment-shines-at-aan-2025 2025-08-22T14:19:08+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/advancing-neurodegenerative-disease-research-at-adpdtm-2025-international-conference-on-alzheimer-s-and-parkinson-s-diseases-and-related-neurological-disorders 2025-08-22T14:19:27+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/from-knowledge-to-action-empowering-the-mogad-community 2025-08-22T14:14:18+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/world-parkinson-s-day-2025-driving-change-through-collaboration 2025-04-14T16:48:09+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/the-evolving-role-of-real-world-evidence-in-secondary-fracture-prevention 2025-08-21T17:24:27+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/transforming-patient-care-ucb-partners-with-smartpatient-to-support-people-living-with-psoriasis 2025-04-30T09:48:10+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/world-as-day-2025-making-the-invisible-visible-kelly-fraser-s-story 2025-08-22T14:13:27+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/world-as-day-2025-why-earlier-diagnosis-of-axspa-is-critical-for-better-outcomes 2025-05-05T15:25:15+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/patient-engagement-key-to-be-sustainable 2025-08-13T11:44:50+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/ucb-and-domino-data-lab-team-up 2025-08-22T14:10:33+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/advancing-care-at-the-intersection-of-rheumatology-and-pregnancy-key-takeaways-from-rheumapreg-2025 2025-06-03T14:02:01+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/innovation-in-rheumatology-at-eular-2025 2025-08-21T16:59:39+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/are-traditional-clinical-trials-on-the-brink-of-obsolescence 2025-06-11T13:23:35+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/shining-a-light-on-myasthenia-gravis-ucb-marks-mg-awareness-month-and-previews-faces-of-mg 2025-08-13T11:39:08+02:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/expanding-our-us-manufacturing-footprint 2025-06-12T20:27:18+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/it-s-more-than-seizures-understanding-developmental-and-epileptic-encephalopathy-disruptions 2025-06-23T13:44:22+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/rethinking-myasthenia-gravis-bridging-gaps-and-creating-lasting-change 2025-08-13T11:36:55+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/hlth-europe-2025-highlights-how-ai-ecosystems-and-evidence-are-redefining-healthcare 2025-06-27T09:56:11+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/charting-the-course-ucb-s-latest-research-on-tk2d-illuminates-patient-journeys 2025-08-12T14:31:01+02:00 0.5 https://www.ucb.com/investors/magazine/detail/article/stronger-every-semester-from-differentiated-innovation-to-outstanding-delivery 2025-08-13T11:59:16+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/navigating-the-barriers-to-identifying-and-treating-developmental-and-epileptic-encephalopathies-in-adults 2025-08-29T11:03:11+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/raising-awareness-building-hope-cultivating-support-and-solutions-for-the-tk2d-community 2025-09-09T13:23:07+02:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/driving-progress-for-people-living-with-dermatological-conditions-at-eadv-2025 2025-09-22T10:46:04+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/transforming-axial-spondyloarthritis-diagnosis-with-fastrax-in-france 2025-10-16T11:44:28+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/carecompass-transforming-the-care-journey-of-caregivers-and-their-loved-ones-with-dravet-syndrome-or-lennox-gastaut-syndrome 2025-10-16T11:35:12+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/can-collaboration-transform-care-in-rare-disease-ucb-s-mission-in-community-driven-digital-solutions 2025-10-16T17:06:42+02:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/multidisciplinary-collaboration-as-the-future-of-patient-centered-care 2025-11-05T13:54:25+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/closing-the-care-gap-optimizing-post-fracture-care-in-osteoporosis-through-fan 2025-10-29T09:15:04+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/bridging-the-communication-gap-in-myasthenia-gravis-insights-from-the-engage-program 2025-10-30T15:02:06+01:00 0.5 https://www.ucb.com/innovation/magazine/detail/article/how-fastrax-is-transforming-patient-care-and-proving-that-innovation-can-scale 2025-11-06T13:38:40+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/confronting-the-challenges-of-prolonged-seizures 2025-11-07T16:54:39+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/ucb-s-unwavering-commitment-to-shaping-the-future-of-hidradenitis-suppurativa 2025-12-03T08:49:41+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/understanding-the-full-impact-of-cdkl5-deficiency-disorder 2025-12-08T10:15:17+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/from-pilot-to-practice-reflections-from-ucb-s-epilepsy-digital-roundtable-on-scaling-go-to-market-strategies 2025-12-19T15:12:01+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/ucb-community-health-fund-enters-a-new-phase 2026-02-17T17:26:18+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/rare-disease-day-more-than-you-can-imagine 2026-02-24T14:40:33+01:00 0.5 https://www.ucb.com/investors/magazine/detail/article/strong-execution-in-service-of-patients-and-sustainable-value 2026-02-26T14:39:35+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/international-women-s-day-2026-when-we-give-women-of-childbearing-age-the-data-they-deserve-we-all-gain 2026-03-06T16:25:45+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/driving-change-for-epilepsy-care-in-rwanda 2026-03-12T16:54:40+01:00 0.5 https://www.ucb.com/about-ucb/magazine/detail/article/growing-our-us-roots-with-a-new-facility-in-georgia 2026-03-24T20:03:02+01:00 0.5 https://www.ucb.com/solutions/magazine/detail/article/evolving-expectations-in-immunologic-disease-our-work-with-those-living-with-immune-mediated-diseases-and-hcps 2026-03-30T14:55:33+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Alprazolam 2026-03-30T16:24:12+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Prostavasin-alprostadil 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Kemstro-baclofen 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/bimekizumab-UCB4940 2026-03-30T16:24:12+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/brivaracetam 2026-02-02T14:46:34+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Parcopa-carbidopa-levodopa 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/CDP323 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/CDP791 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Cimzia 2026-01-08T15:32:55+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Dapirolizumab-pegol 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/epratuzumab 2026-01-08T15:32:55+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Ferro-Sanol-ferrous-II-glycine-sulphate-complex 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Vimpat-lacosamide 2026-02-02T14:46:39+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Keppra-levetiracetam 2026-02-02T14:46:34+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Xyzal-levocetirizine 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Olokizumzab 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Nootropil-piracetam 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Radiprodil 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/EVENITY-Romosozumab 2026-01-08T15:32:55+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Seletracetam 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Staccat-Alprazolam 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Padsevonil-UCB0942 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Seletalisib-UCB5857 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Zampilimab-UCB7858 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB0599 2025-11-11T12:11:15+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/ucb6114 2024-11-18T09:50:49+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB7853 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Bepranemab-UCB0107 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB0022 2024-11-18T09:50:49+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB9741 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/UCB1381 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Hydrocodone%20bitartrate%20extended%20release%20%28HC-ER%29 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Intraject%C2%AE%C2%A0Sumatriptan 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Hydrocodone%20Bitartrate%20controlled%20release%20%28HC-CR%29 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Risperidone-SABER%C2%AE 2025-11-06T15:05:28+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Fenfluramine%20%20%28Fintepla%29 2026-02-02T14:46:34+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/mt1621 2024-11-18T09:50:49+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Doxecitine%20and%20doxribtimine%20%28MT1621%29 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Ginisortamab%20%28UCB6114%29 2025-11-06T15:05:24+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Rozanolixizumab-UCB7665 2026-02-02T14:46:39+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Zilucoplan-RA101495 2026-02-02T14:46:39+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Neupro-rotigotine 2026-01-08T15:32:55+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Glovadalen%20%28UCB0022%29 2025-11-11T12:11:15+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Doxecitine%20and%20doxribtimine 2026-01-07T17:06:40+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/clinical-studies-index/Galvokimig%20%28UCB9741%29 2026-02-02T14:46:34+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PS0009 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=AS0014 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PA0012 2025-06-25T12:11:15+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PSP002 2025-07-28T07:43:55+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PS0007 2026-02-16T20:04:30+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=EP0156 2025-06-05T13:03:11+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=SL0046 2025-08-29T15:51:51+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=EP0162 2025-02-24T12:32:35+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=EP0165 2025-10-09T08:11:41+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=RA101495-02.302 2025-01-10T10:57:00+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=N01269 2026-03-04T18:50:36+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=MOG001 2026-03-11T06:39:08+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=HS0005 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PS0026 2024-01-03T16:51:13+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=ZX008-2103 2023-01-16T11:20:01+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=MG0014 2025-02-24T12:35:27+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=TK0102 2025-06-25T12:12:45+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=EP0213 2025-09-04T09:44:17+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=MG0006 2024-06-24T11:24:19+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PS0021 2024-07-25T22:31:55+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=EP0224 2024-07-25T22:32:09+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=MG0015 2026-02-17T11:14:46+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PS0039 2025-05-27T17:20:02+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=MG0008 2025-02-24T12:34:14+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PA0016 2026-03-12T08:55:02+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=SL0044 2026-02-02T16:20:03+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=JA0005 2025-12-17T19:51:35+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=HS0006 2025-06-25T12:10:32+02:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=UP0122 2025-12-01T10:57:44+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=MG0033 2025-12-10T12:00:15+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PPP001 2025-12-04T12:28:01+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=PA0019 2026-01-08T08:55:02+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=ATD002 2026-01-27T08:35:02+01:00 0.5 https://www.ucb.com/innovation/clinical-studies/current-studies?studyId=MG0038 2026-03-13T09:10:02+01:00 0.5